Rob Dillard

DocwireNews

Over 50% of patients with advanced non-small cell lung cancer (aNSCLC) are untested for biomarkers, according to a study <a href="https://onlinelibrary.wiley.com/doi/10.1002/cam4.6694" target="_blank" rel="noopener">published</a> in Cancer Medicine.&ldquo;Characteristics of patients in clinical trials may differ from those of real-world patients. Our objective was to describe biomarker testing and outcomes among patients with aNSCLC in a real-world setting,&rdquo; the researchers wrote.In this retrospective cohort study, researchers used the TEMPUS oncology dataset to assess 9,540 patients &ge;18 years old, diagnosed with stage IIIB/C or IV NSCLC from January 1, 2012, to December 31, 2020. The investigators noted that patient characteristics associated with biomarker testing were evaluated in patients with positive biomarkers using univariate logistic regression models, while Cox proportional hazard modeling was used to estimate survival.The findings showed that 41.7% had biomarker testing, and 2.158 had a positive biomarker result. The investigators found that men, Black patients, patients with squamous or unknown histology (vs non-squamous histology), and patients with an Eastern Cooperative Oncology Group performance status of 2+ were less likely to undergo biomarker testing. Moreover, the results showed that the almost 56% of patients with positive biomarkers who received NCCN-recommended treatment options&nbsp; had a notably longer median overall survival(hazard ratio [HR], 0.84; 95% CI: 0.75-0.95) and real-world progression-free survival (HR, 0.68; 95% CI: 0.62-0.75).The researchers concluded that adherence to targeted treatment &ldquo;improves real-world clinical outcomes among patients with aNSCLC and positive biomarkers.&rdquo;

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

Over Half of Advanced Non-Small Cell Lung Cancer Patients Are Untested for Biomarkers

Non-Small Cell Lung Cancer

Over 50% of patients with advanced non-small cell lung cancer are untested for biomarkers.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe